Newsroom | 49569 results

ENGLEWOOD, N.J.--(BUSINESS WIRE)--SpotitEarly, an early cancer detection startup that uses AI and trained canines to identify cancer odor signatures in breath samples, today announced a strategic partnership with the Fox Chase Cancer Center, which includes the Institute for Cancer Research and the American Oncologic Hospital and is a part of Temple Health. SpotitEarly’s partnership with the nationally recognized leader in oncology innovation, with a history of accelerating cancer breakthroughs,...

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that the U.S. Food and Drug Administration (FDA) has approved Guardant360® CDx as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC) who may benefit from treatment with BRAFTOVI® (encorafenib) in combination with cetuximab and chemotherapy in accordance with the approved product labeling. The accelerated approval was su...

LAS VEGAS--(BUSINESS WIRE)--Gilad&Gilad launches AgmaVet® For Horses containing the neuroprotective ingredient G-Agmatine® for resilient nerve functions and joints mobility....

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that ROSELLA, the company’s pivotal Phase 3 trial of relacorilant plus nab-paclitaxel to treat patients with platinum-resistant ovarian cancer, met its overall survival (OS) primary...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda (TSE:4502/NYSE:TAK) today announced the U.S. availability of GAMMAGARD LIQUID™ ERC [immune globulin infusion (human)] with less than or equal to 2 µg/mL IgA in a 10% solution, by prescription, approved as replacement therapy for people two years of age and older with primary immunodeficiency (PI). GAMMAGARD LIQUID ERC is a liquid immunoglobulin therapy that does not require reconstitution and has a low immunoglobulin A (IgA) content less than or equal t...

CONCORD, Calif.--(BUSINESS WIRE)--Cerus Corporation (Nasdaq: CERS) today announced the start of the INITIATE study by the German Red Cross Blood Donation Service Baden-Württemberg – Hessen and its subsidiary organization, the German Red Cross Blood Donation Service North-East. The prospective, multicenter, non-interventional safety study, sponsored by DRK Blood Donation Service Baden-Württemberg-Hessen, is the first of its kind in Germany to evaluate the routine use of pathogen-inactivated plat...

BALTIMORE--(BUSINESS WIRE)--ReGelTec Inc., a company developing a percutaneous hydrogel implant for the treatment of chronic low back pain caused by degenerative disc disease, announced the publication of a journal article in Pain Physician demonstrating that its HYDRAFIL System for disc augmentation safely generated lasting clinically significant improvements in pain and disability scores in patients with chronic low back pain due to degenerative disc disease. The HYDRAFIL System is an outpati...

TAMPA, Fla.--(BUSINESS WIRE)--Concept Medical Inc. is proud to announce the successful enrollment of the first patients in the STARS DAPT randomized controlled trial....

IRVING, Texas--(BUSINESS WIRE)--The 2026 Vizient state of the industry report highlights structural pressure, financial risk and opportunities for resilience....

LEIDEN, Netherlands--(BUSINESS WIRE)--Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that its lead asset, nizubaglustat, will feature in five scientific presentations accepted at the WORLDSymposium™ 2026, the leading global conference on lysosomal diseases, taking place in San Diego, California, USA between February 2-6. The company’s conference activities include: Oral Presentations (...